Wespac Advisors, LLC Eli Lilly & CO Transaction History

Wespac Advisors, LLC

$131 Million
Q3 2024

A detailed history of Wespac Advisors, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Wespac Advisors, LLC holds 2,459 shares of LLY stock, worth $1.89 Million. This represents 1.67% of its overall portfolio holdings.

Number of Shares

2,459

Previous 2,375 3.54%

Holding current value

$1.89 Million

Previous $2.15 Million 1.3%

% of portfolio

1.67%

Previous 1.74%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$772.14 - $960.02 $64,859 - $80,641	84 Added 3.54%	2,459 $2.18 Million
Q2 2024 Jul 30, 2024	SELL	$724.87 - $909.04 $350,837 - $439,975	-484 Reduced 16.93%	2,375 $2.15 Million
Q1 2024 Apr 24, 2024	BUY	$592.2 - $792.28 $190,688 - $255,114	322 Added 12.69%	2,859 $2.22 Million
Q4 2023 Jan 25, 2024	BUY	$525.19 - $619.13 $185,392 - $218,552	353 Added 16.16%	2,537 $1.48 Million
Q3 2023 Oct 25, 2023	BUY	$434.7 - $599.3 $172,575 - $237,922	397 Added 22.22%	2,184 $1.17 Million
Q1 2023 Apr 26, 2023	SELL	$310.63 - $364.82 $301,932 - $354,605	-972 Reduced 35.23%	1,787 $613,000
Q4 2022 Jan 31, 2023	BUY	$321.55 - $374.67 $32,155 - $37,467	100 Added 3.76%	2,759 $1.01 Million
Q3 2022 Oct 18, 2022	BUY	$296.48 - $337.87 $788,340 - $898,396	2,659 New	2,659 $860,000
Q2 2021 Aug 03, 2021	SELL	$180.55 - $233.54 $234,715 - $303,602	-1,300 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$164.32 - $212.72 $213,616 - $276,536	1,300 New	1,300 $243,000
Q2 2019 Jul 23, 2019	SELL	$110.79 - $129.32 $2.21 Million - $2.58 Million	-19,935 Closed	0 $0
Q1 2019 Apr 19, 2019	BUY	$111.31 - $131.02 $2.22 Million - $2.61 Million	19,935 New	19,935 $2.59 Million

Others Institutions Holding LLY

# of Institutions

4,011

Shares Held

751M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $730B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wespac Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wespac Advisors, LLC with notifications on news.

Account

Wespac Advisors, LLC Eli Lilly & CO Transaction History